Jul. 10, 2011
On July 11, 2011 3SBio reported that the SFDA has approved its high-dose formulation of EPIAO, a treatment for chemotherapy-induced anemia. High dose EPIAO is designed to rapidly restore hemoglobin to normal levels in cancer patients. The 36,000 IU dosage is comparable to the standardized dose used globally for chemotherapy-induced anemia, allowing for less frequent administration than lower dosage forms, which in turn is expected to provide greater convenience for both patients and caregivers.